Cel Sci Corp (CVM) Stock Price & Analysis
Cel Sci Corp (CVM) fell 5.80% to USD 1.3 as of June 10, 2026 at 07:32 UTC, according to Nexqual real-time market data.
CVM last closed at USD 1.38; the session ranged USD 1.3–1.43 on volume of 235,239 shares. Market capitalization is $18.84M, with a 52-week range of USD 0.89–13.48 (ASE). Source: Nexqual, June 10, 2026 at 07:32 UTC.
Key Statistics (as of June 10, 2026 at 07:32 UTC)
| Price | USD 1.3 |
|---|---|
| Change | ▼ 5.80% (down) |
| Previous Close | USD 1.38 |
| Open | USD 1.35 |
| Day Range | USD 1.3 – 1.43 |
| 52-Week Range | USD 0.89 – 13.48 |
| Volume | 235,239 shares |
| Market Cap | $18.84M |
| Exchange | ASE |
Technical Analysis (CVM)
Nexqual's technical model rates CVM "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:32 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.99 (oversold) |
| vs SMA50 | Below (USD 2.59) |
| MACD | -0.29 (negative) |
Analyst Ratings (CVM)
Wall Street analysts rate CVM "None", per Nexqual as of June 10, 2026 at 07:32 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CVM)
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financials & Fundamentals (CVM)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -305.27% |
| Debt / Equity | 123.82 |
| Current Ratio | 0.6 |
| Total Cash | $1.90M |
| Total Debt | $8.51M |
| Free Cash Flow | $-9.23M |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Financial Health Score (CVM)
Nexqual rates Cel Sci Corp's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:32 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $2M cash vs $9M debt |
| Cash Flow | Weak — Operating cash flow -$17M |
| Efficiency | Critical — ROE -305%, ROA -70.3% |
Ownership (CVM)
| Insider Ownership | +5.46% |
|---|---|
| Institutional Ownership | +5.36% |
| Shares Outstanding | 14.49M |
| Float | 8.17M |
| Short % of Float | +1.60% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
Leadership (CVM)
Cel Sci Corp is led by Geert R. Kersten (age 66), Chief Executive & Financial Officer, CAO,Treasurer and Director, per Nexqual as of June 10, 2026 at 07:32 UTC.
| Chief Executive & Financial Officer, CAO,Treasurer and Director | Geert R. Kersten (age 66) |
|---|---|
| Chief Financial & Operations Officer, Compliance Officer & Corporate Secretary | Patricia B. Prichep (age 74) |
| Chief Scientific Officer | Eyal Talor (age 69) |
| Senior Vice President of Regulatory Affairs | John Cipriano (age 83) |
Major Backers & Investors (CVM)
Notable institutional backers of Cel Sci Corp include MAI Capital Management, Fidelity, Bank of America Corporation, according to Nexqual as of June 10, 2026 at 07:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MAI Capital Management | 1.07% |
| Fidelity | 0.78% |
| Bank of America Corporation | 0.48% |
| Renaissance Technologies | 0.42% |
| US BANCORP \DE\ | 0.35% |
| Xtx Topco Ltd | 0.27% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.32% |
| Geode Capital | 1% |
| BlackRock | 0.51% |
| State Street | 0.32% |
Source: Nexqual, June 10, 2026 at 07:32 UTC.
From Cel Sci Corp's Latest SEC 10-K Filing (filed 2025-12-29)
Key Strengths & Strategy (as disclosed to the SEC)
- CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.
- The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
- It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis.
- In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments.
Partnerships
- CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AGEN | Agenus Inc. | USD 3.11 | ▼ 3.72% |
| BGMSP | Bio Green Med Solution Inc. | USD 0.7 | ▲ 0.86% |
| CSCIF | COSCIENS Biopharma Inc | USD 2.05 | ▲ 12.64% |
| CRIS | Curis, Inc. | USD 0.45 | ▼ 4.87% |
| BCRX | BioCryst Pharmaceuticals, Inc. | USD 8.33 | ▼ 0.95% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:32 UTC. This page is informational and not investment advice.